Literature DB >> 31672293

Treatment of Gastroenteropancreatic Neuroendocrine Tumors.

Kimberly Perez1, Jennifer Chan2.   

Abstract

Neuroendocrine tumors (NETs) represent a group of biologically and clinically heterogeneous neoplasms arising from the diffuse neuroendocrine system. Although NETs may develop in almost any organ, they commonly arise in the gastrointestinal tract and pancreas and are referred to as gastroenteropancreatic (GEP)-NETs when they arise from these sites. In recent years, advances in understanding of the biology of NETs have resulted in an expansion in treatment options and improved survival for patients. This review focuses on treatment of GEP-NETS and highlights factors that govern the therapeutic approach.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gastroenteropancreatic; Gastrointestinal tract; Neuroendocrine system; Neuroendocrine tumors

Mesh:

Substances:

Year:  2019        PMID: 31672293     DOI: 10.1016/j.path.2019.08.011

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  6 in total

1.  Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy.

Authors:  Catherine G Tran; Luis C Borbon; Jacqueline L Mudd; Ellen Abusada; Solmaz AghaAmiri; Sukhen C Ghosh; Servando Hernandez Vargas; Guiying Li; Gabriella V Beyer; Mary McDonough; Rachel Li; Carlos H F Chan; Susan A Walsh; Thaddeus J Wadas; Thomas O'Dorisio; M Sue O'Dorisio; Ramaswamy Govindan; Paul F Cliften; Ali Azhdarinia; Andrew M Bellizzi; Ryan C Fields; James R Howe; Po Hien Ear
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

Review 2.  Treatment personalization in gastrointestinal neuroendocrine tumors.

Authors:  Chiara Borga; Gianluca Businello; Sabina Murgioni; Francesca Bergamo; Chiara Martini; Eugenio De Carlo; Elisabetta Trevellin; Roberto Vettor; Matteo Fassan
Journal:  Curr Treat Options Oncol       Date:  2021-02-27

3.  Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis.

Authors:  Alberto Bongiovanni; Chiara Liverani; Federica Recine; Valentina Fausti; Laura Mercatali; Alessandro Vagheggini; Chiara Spadazzi; Giacomo Miserocchi; Claudia Cocchi; Giandomenico Di Menna; Alessandro De Vita; Stefano Severi; Silvia Nicolini; Toni Ibrahim
Journal:  Front Oncol       Date:  2020-04-07       Impact factor: 6.244

4.  Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours.

Authors:  Karen Rico; Suzann Duan; Ritu L Pandey; Yuliang Chen; Jayati T Chakrabarti; Julie Starr; Yana Zavros; Tobias Else; Bryson W Katona; David C Metz; Juanita L Merchant
Journal:  BMJ Open Gastroenterol       Date:  2021-11

5.  Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting.

Authors:  Alejandro Mejia; Elaina Vivian; Christiana Nwogu; Jimmy Shah; Raquel Longoria; Allison Vo; Islam Shahin; Jonathan Verma; Alexandru Bageac
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

Review 6.  Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Kristen McClellan; Emerson Y Chen; Adel Kardosh; Charles D Lopez; Jaydira Del Rivero; Nadine Mallak; Flavio G Rocha; Yilun Koethe; Rodney Pommier; Erik Mittra; Guillaume J Pegna
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.